Q-omics provides the consensus-scored CXCL12 profile across patient tissues and cancer cell-line models. CXCL12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CXCL12 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, CXCL12 protein abundance shows 28,813 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, KICH, and LUAD as cancer lineages where CXCL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL12 survival associations across molecular data types. CXCL12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL12 RNA expression–survival associations across cancer types. High CXCL12 expression shows unfavorable associations in BLCA and UVM, but favorable associations in SKCM, UCS, KIRC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CXCL12 RNA expression.
This table summarizes CXCL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CXCL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL12 shows lower tumor expression in KICH, BLCA, COAD, KIRP, THCA and KIRC. The KICH box plot shows higher CXCL12 RNA expression in normal versus tumor tissue (log2 FC = −4.352, t-test p < 0.001).
This table shows molecular features associated with CXCL12 in patient tissues and cancer cell lines. In patient samples, CXCL12 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
